New York, November 07, 2014 -- Moody's Investors Service placed the ratings of Salix Pharmaceuticals, Ltd ("Salix") under review for downgrade. This rating action reflects the disclosure of significantly higher-than-expected inventory at drug wholesalers, which will result in lower sales expectations going forward as the inventory is worked down. The Speculative Grade Liquidity Rating is lowered from to SGL-2 from SGL-1.
Vollständigen Artikel bei Moodys lesen